NCT02106923 - Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions

Healthy

Interventions

DRUG

1 tablet Empagliflozin/2 tablets Metformin XR

Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

DRUG

10 mg Empagliflozin/1000 mg Metformin XR

Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

DRUG

1 tablet 10 mg Empagliflozin/3 tablets Metformin XR

Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets

DRUG

2 tablets 5 mg Empagliflozin/750 Metformin XR

Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets

DRUG

1 tablet Empagliflozin/2 tablets Metformin XR

Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

DRUG

10 mg Empagliflozin/1000 mg Metformin XR

Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

Trial Locations (1)

Boehringer Ingelheim Investigational Site, Austin